Cook, LolaSchulze, JeanineUhlmann, Wendy R.Verbrugge, JenniferMarder, KarenLee, Annie J.Wang, YuanjiaAlcalay, Roy N.Nance, MarthaBeck, James C.2023-10-112023-10-112022-11-29Cook L, Schulze J, Uhlmann WR, et al. Tools for communicating risk for Parkinson's disease. NPJ Parkinsons Dis. 2022;8(1):164. Published 2022 Nov 29. doi:10.1038/s41531-022-00432-6https://hdl.handle.net/1805/36288We have greater knowledge about the genetic contributions to Parkinson’s disease (PD) with major gene discoveries occurring in the last few decades and the identification of risk alleles revealed by genome-wide association studies (GWAS). This has led to increased genetic testing fueled by both patient and consumer interest and emerging clinical trials targeting genetic forms of the disease. Attention has turned to prodromal forms of neurodegenerative diseases, including PD, resulting in assessments of individuals at risk, with genetic testing often included in the evaluation. These trends suggest that neurologists, clinical geneticists, genetic counselors, and other clinicians across primary care and various specialties should be prepared to answer questions about PD genetic risks and test results. The aim of this article is to provide genetic information for professionals to use in their communication to patients and families who have experienced PD. This includes up-to-date information on PD genes, variants, inheritance patterns, and chances of disease to be used for risk counseling, as well as insurance considerations and ethical issues.en-USAttribution 4.0 InternationalParkinson's diseaseNeurologyGenome-wide association studiesArticle